Form 4: AngioDynamics CFO Buys Shares in Open Market
Insider Transaction Report
AngioDynamics' EVP and CFO, Stephen A. Trowbridge, purchased 890 shares of common stock at $11.16 per share, increasing his direct beneficial ownership.
Summary
- Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer of AngioDynamics Inc. (ANGO), acquired 890 shares of common stock.
- The transaction occurred on October 13, 2025, at a price of $11.16 per share.
- This purchase was made pursuant to a Rule 10b5-1 trading plan.
- Following this transaction, Mr. Trowbridge directly beneficially owns 256,629 shares of AngioDynamics common stock.
Sentiment
Score: 7
Explanation: The purchase of common stock by a key executive signals confidence in the company's future prospects, which is generally a positive sentiment indicator.
Positives
- The EVP and CFO's purchase of common stock signals strong insider confidence in the company's current valuation and future prospects.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reactive decision.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
Insider buying, particularly by a high-ranking financial executive, is often viewed by the market as a positive indicator of management's confidence in the company's intrinsic value and future growth prospects, potentially signaling a belief that the stock is undervalued.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 10/13/2025 | Indicates a pre-arranged trading strategy, reducing the perception of opportunistic trading and aligning executive interests with long-term company performance. |
Stakeholder Impact
- Shareholders: The insider purchase may instill greater confidence among existing shareholders and attract potential investors, as it suggests management believes the stock is a good investment.
- Employees: May signal stability and positive outlook for the company's future.
Key Dates
| Date | Description |
|---|---|
| 10/13/2025 | Date of common stock acquisition by Stephen A. Trowbridge. |
| 10/14/2025 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed and filed. |
Recommendation
buyThe purchase of common stock by a high-ranking executive, the EVP and CFO, demonstrates strong insider confidence in AngioDynamics' valuation and future performance. Such direct investment by management is often interpreted as a positive signal for investors, suggesting that the executive believes the shares are undervalued or poised for growth. While not a sole determinant, it provides a compelling reason to consider a 'buy' recommendation, especially when combined with other positive fundamental analysis.
Keywords
ANGIODYNAMICS, ANGO, Insider Trading, Share Purchase, CFO, Stephen A. Trowbridge, Form 4, Equity Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.